|By Marketwired .||
|June 16, 2014 03:58 PM EDT||
BUFFALO, NY -- (Marketwired) -- 06/16/14 -- Rand Capital Corporation (NASDAQ: RAND), a business development company that provides capital and managerial expertise for small and medium-sized private companies, notes that its Ithaca, New York-based portfolio company, Rheonix, Inc., has received six new patents over the last nine months (http://www.rheonix.com/press/RHE_patent%20release_FINAL.pdf) and has earned a fast-track grant from the National Institutes of Health (NIH) to complete an automated system for simultaneous HIV detection and confirmation. The six-month Phase I award from the NIH is for $189,646, and it is expected to be followed by an 18-month Phase II award of approximately $1.5 million (http://www.rheonix.com/press/NIH_NYU_Grant%20Announcement%20FINAL.pdf). This follow-on funding is in addition to the $30 million raised in late 2013, in a combination of debt and equity investments led by Rand Capital SBIC, Inc., a subsidiary of Rand Capital Corporation (NASDAQ: RAND), and Cayuga Venture Fund.
Allen F. "Pete" Grum, president of Rand Capital, said, "We are pleased to be an investor in Rheonix, a company that will transform the molecular diagnostics and testing industry by bringing complete automation to the high-volume molecular assay market, a segment that is not being adequately served today."
Rheonix is a developer of fully automated molecular testing solutions, including the Chemistry and Reagent Device (CARD®) cartridge and EncompassMDx molecular testing platform. The Rheonix CARD is a disposable cartridge the size of a credit card that runs multiple samples simultaneously without user intervention. Once a raw sample is placed on the CARD, the automated EncompassMDx platform runs through the process of sample extraction, DNA purification, amplification, and detection. The sample-to-result solution eliminates the need for multiple pieces of existing equipment, helping to make the testing process quicker, more efficient, less expensive, and less likely to result in human error.
Rheonix technology builds upon recent industry developments, including complete automation from sample input through endpoint detection, as well as the use of panels that provide clinicians with useful information rather than raw data and help improve the standard of care for patients.
"From the beginning, Rheonix has focused on manufacturability. All of our research and development efforts have been grounded in the belief that emerging products must be robust yet low-cost in regard to material selection and assembly," said Tony Eisenhut, President of Rheonix.
The company is in the midst of expanding its physical operations to produce consumables and systems to fulfill Rheonix's joint development agreement with Life Technologies Corp. (http://www.rheonix.com/press/RheonixLIFEPressRelease.pdf) and to commercialize its first clinical, molecular diagnostic product offering later in 2014.
For more information on Rheonix and its products, please visit www.rheonix.com.
About Rheonix Inc.: Rheonix Inc. is committed to improving standards of care by making molecular diagnostics available to more people, in more places, more often. Rheonix, through experienced leadership and creative vision, has developed the EncompassMDx platform, a highly customizable technology with unmatched versatility and affordability. The platform performs fully automated, complex molecular assays in an easy-to-use and economical format on the Rheonix CARD® cartridge. With both the Rheonix CARD and EncompassMDx family of products, Rheonix is well-positioned to penetrate key molecular diagnostic market sectors, from reference labs through point-of-care and everywhere in between. For more information, visit www.rheonix.com.
About Rand Capital: Rand Capital is a publicly held Business Development Company (BDC), and its wholly owned subsidiary is licensed by the Small Business Administration (SBA) as a Small Business Investment Company (SBIC). Rand provides capital and managerial expertise to small and medium-sized private companies primarily located in the northeast U.S. Rand is traded on the NASDAQ under the symbol "RAND" and is headquartered in Buffalo, New York. For more information, visit www.randcapital.com.
Allen F. Grum
UpGuard has become a member of the Center for Internet Security (CIS), and will continue to help businesses expand visibility into their cyber risk by providing hardening benchmarks to all customers. By incorporating these benchmarks, UpGuard's CSTAR solution builds on its lead in providing the most complete assessment of both internal and external cyber risk. CIS benchmarks are a widely accepted set of hardening guidelines that have been publicly available for years. Numerous solutions exist t...
Jul. 25, 2016 06:15 PM EDT Reads: 395
A critical component of any IoT project is what to do with all the data being generated. This data needs to be captured, processed, structured, and stored in a way to facilitate different kinds of queries. Traditional data warehouse and analytical systems are mature technologies that can be used to handle certain kinds of queries, but they are not always well suited to many problems, particularly when there is a need for real-time insights.
Jul. 25, 2016 06:15 PM EDT Reads: 1,713
Jul. 25, 2016 06:00 PM EDT Reads: 2,070
Jul. 25, 2016 06:00 PM EDT Reads: 1,407
Jul. 25, 2016 06:00 PM EDT Reads: 2,392
Jul. 25, 2016 05:30 PM EDT Reads: 736
Jul. 25, 2016 04:38 PM EDT Reads: 156
Jul. 25, 2016 04:00 PM EDT Reads: 993
Jul. 25, 2016 03:45 PM EDT Reads: 943
Jul. 25, 2016 03:30 PM EDT Reads: 1,684
Jul. 25, 2016 03:15 PM EDT Reads: 417
Jul. 25, 2016 03:00 PM EDT Reads: 1,969
Jul. 25, 2016 02:45 PM EDT Reads: 859
Jul. 25, 2016 02:30 PM EDT Reads: 866
Jul. 25, 2016 02:00 PM EDT Reads: 956